1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with Psychoses, Drug in 4 studies
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This reduction of parkinsonism was not accompanied by an exacerbation of dyskinesia or PLBs." | 1.56 | Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset. ( Bédard, D; Frouni, I; Gourdon, JC; Hamadjida, A; Huot, P; Kwan, C; Nuara, SG, 2020) |
| "Nefazodone is an anti-depressant that interacts with a wealth of pharmacological targets, including some that may exert anti-dyskinetic and anti-psychotic effects in Parkinson's disease (PD), notably serotonin 1A and 2A receptors." | 1.48 | Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset. ( Bédard, D; Frouni, I; Gourdon, JC; Hamadjida, A; Huot, P; Kwan, C; Nuara, SG, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hamadjida, A | 2 |
| Nuara, SG | 2 |
| Kwan, C | 2 |
| Frouni, I | 2 |
| Bédard, D | 2 |
| Gourdon, JC | 2 |
| Huot, P | 2 |
| Lang, AE | 1 |
| Blair, RD | 1 |
| Donaldson, J | 1 |
2 reviews available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Psychoses, Drug
| Article | Year |
|---|---|
Parkinson's disease in 1984: an update.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Dementia; Drug Therapy, Combination; Dy | 1984 |
The physiopathologic significance of manganese in brain: its relation to schizophrenia and neurodegenerative disorders.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blood Glucose; Brain; Brain Chemistry; Chile; | 1987 |
2 other studies available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Psychoses, Drug
| Article | Year |
|---|---|
Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Behavior | 2020 |
Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Calli | 2018 |